Based on these data, small molecule Dagla inhibitors with a pharmacokinetic profile similar to that of Cnr1 inverse agonists are likely to mirror the ability of these inverse agonists to decrease food intake, BW, TGs, and insulin resistance while improving glycemic control in obese patients with diabetes. This evidence concerns the gene DAGLA and diabetes mellitus.